Gables Capital Management’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $414K | Hold |
7,190
| – | – | 0.15% | 107 |
|
|
2026
Q1 | $436K | Sell |
7,190
-69
| -1% | -$4.02K | 0.18% | 90 |
|
|
2025
Q4 | $392K | Hold |
7,259
| – | – | 0.17% | 100 |
|
|
2025
Q3 | $327K | Sell |
7,259
-350
| -5% | -$16.3K | 0.14% | 106 |
|
|
2025
Q2 | $352K | Sell |
7,609
-50
| -0.7% | -$2.45K | 0.17% | 100 |
|
|
2025
Q1 | $467K | Hold |
7,659
| – | – | 0.23% | 82 |
|
|
2024
Q4 | $433K | Sell |
7,659
-900
| -11% | -$50.3K | 0.21% | 80 |
|
|
2024
Q3 | $443K | Sell |
8,559
-125
| -1% | -$5.86K | 0.22% | 83 |
|
|
2024
Q2 | $361K | Hold |
8,684
| – | – | 0.19% | 90 |
|
|
2024
Q1 | $471K | Buy |
8,684
+750
| +9% | +$38.2K | 0.26% | 76 |
|
|
2023
Q4 | $407K | Buy |
7,934
+700
| +10% | +$36.7K | 0.25% | 76 |
|
|
2023
Q3 | $420K | Hold |
7,234
| – | – | 0.29% | 69 |
|
|
2023
Q2 | $463K | Buy |
7,234
+375
| +5% | +$25.1K | 0.3% | 72 |
|
|
2023
Q1 | $475K | Hold |
6,859
| – | – | 0.33% | 64 |
|
|
2022
Q4 | $494K | Sell |
6,859
-100
| -1% | -$7.54K | 0.36% | 65 |
|
|
2022
Q3 | $495K | Hold |
6,959
| – | – | 0.4% | 59 |
|
|
2022
Q2 | $536K | Hold |
6,959
| – | – | 0.4% | 56 |
|
|
2022
Q1 | $508K | Hold |
6,959
| – | – | 0.32% | 72 |
|
|
2021
Q4 | $434K | Hold |
6,959
| – | – | 0.26% | 82 |
|
|
2021
Q3 | $412K | Hold |
6,959
| – | – | 0.27% | 76 |
|
|
2021
Q2 | $465K | Sell |
6,959
-4,075
| -37% | -$266K | 0.32% | 74 |
|
|
2021
Q1 | $697K | Hold |
11,034
| – | – | 0.38% | 68 |
|
|
2020
Q4 | $684K | Hold |
11,034
| – | – | 0.4% | 62 |
|
|
2020
Q3 | $665K | Hold |
11,034
| – | – | 0.43% | 56 |
|
|
2020
Q2 | $649K | Buy |
11,034
+69
| +0.6% | +$4.13K | 0.45% | 57 |
|
|
2020
Q1 | $617K | Buy |
10,965
+131
| +1% | +$8.01K | 0.51% | 52 |
|
|
2019
Q4 | $690K | Buy |
10,834
+3,400
| +46% | +$195K | 0.46% | 63 |
|
|
2019
Q3 | $378K | Hold |
7,434
| – | – | 0.27% | 82 |
|
|
2019
Q2 | $340K | Sell |
7,434
-100
| -1% | -$4.66K | 0.28% | 75 |
|
|
2019
Q1 | $359K | Sell |
7,534
-1,200
| -14% | -$59.8K | 0.29% | 76 |
|
|
2018
Q4 | $454K | Sell |
8,734
-1,900
| -18% | -$102K | 0.4% | 62 |
|
|
2018
Q3 | $660K | Hold |
10,634
| – | – | 0.5% | 56 |
|
|
2018
Q2 | $577K | Buy |
10,634
+800
| +8% | +$43.2K | 0.47% | 59 |
|
|
2018
Q1 | $622K | Buy |
+9,834
| New | +$633K | 0.55% | 54 |
|
Other funds holding BMY
Gables Capital Management's BMY Position: Q2 2026 in Review
Gables Capital Management held its Bristol-Myers Squibb (BMY) position steady in Q2 2026 at 7,190 shares worth $414K. The position accounts for 0.15% of the portfolio, ranked #107.
Gables Capital Management first reported a position in BMY in Q1 2018 and has held it in 34 quarters since. The position peaked at $697K in Q1 2021. 2,508 funds tracked by Wall St. Rank hold BMY as of Q2 2026.
- Gables Capital Management held 7,190 shares of Bristol-Myers Squibb worth $414K as of Q2 2026.
- Gables Capital Management left its Bristol-Myers Squibb share count unchanged in Q2 2026.
- Bristol-Myers Squibb made up 0.15% of Gables Capital Management's portfolio in Q2 2026, its #107 holding.
- Gables Capital Management first reported a position in Bristol-Myers Squibb in Q1 2018 and has held it in 34 quarters since.
- Gables Capital Management's Bristol-Myers Squibb position peaked at $697K in Q1 2021.
- 2,508 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.
Based on Gables Capital Management's 13F filing for Q2 2026, filed 10 Aug 2026.